GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background: After liver injury, the repair process comprises activation and proliferation of hepatic stellate cells (HSCs), which produce extracellular matrix (ECM) proteins. Peroxisome proliferator-activated receptor beta/delta ( PPARβ/δ) is highly expressed in these cells, but its function in liver repair remains incompletely understood. This study investigated whether activation of PPARβ/δ with the ligand GW501516 influenced the fibrotic response to injury from chronic carbon tetrachloride (CCl 4 ) treatment in mice. Wild type and PPARβ/δ-null mice were treated with CCl 4 alone or CCl 4 co-administered with GW501516. To unveil mechanisms underlying the PPARβ/δ-dependent effects, we analyzed the proliferative response of human LX-2 HSCs to GW501516 in the presence or absence of PPARβ/δ. Results: We found that GW501516 treatment enhanced the fibrotic response. Compared to the other experimental groups, CCl 4 /GW501516-treated wild type mice exhibited increased expression of various profibrotic and pro-inflammatory genes, such as those involved in extracellular matrix deposition and macrophage recruitment. Importantly, compared to healthy liver, hepatic fibrotic tissues from alcoholic patients showed increased expression of several PPAR target genes, including phosphoinositide-dependent kinase-1, transforming growth factor beta-1, and monocyte chemoattractant protein-1. GW501516 stimulated HSC proliferation that caused enhanced fibrotic and inflammatory responses, by increasing the phosphorylation of p38 and c-Jun N-terminal kinases through the phosphoinositide-3 kinase/protein kinase-C alpha/beta mixed lineage kinase-3 pathway. Conclusions: This study clarified the mechanism underlying GW501516-dependent promotion of hepatic repair by stimulating proliferation of HSCs via the p38 and JNK MAPK pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 6 PPARβ/δ controls pathways that regulate proliferation of LX-2 cells. Stable PPARβ/δ knockdown (KD) was performed by lentiviral transduction of LX-2 cells with a siRNA against PPARβ/δ. Control LX-2 cells were transduced with the control vector. A) qRT-PCR showed reduced PPARβ/δ expression in PPARβ/δ KD LX-2 cells. The control values were set to 1. Results are means ± SD of at least three independent experiments performed in triplicate. B-F) Control and PPARβ/δ KD LX-2 cells were starved for 24 h in serum-free media and then treated for 48 h with DMSO (control) or (B) 100 nM GW501516, or (C-F) 100 nM GW501516 in the presence or absence of 10 nM or 100 nM of (C) PD98059, (D) LY294002, (E) JNK inhibitor II, or (F) SB202190. All inhibitors were added 30 min before GW501516 treatment. Cell proliferation was determined by [3H]-thymidine incorporation. Values are expressed as a percentage of the values from DMSO-treated LX-2 cells, which were set to 100%. Values represent means ± SEM from at least five independent experiments performed in triplicate; * = p<0.05 compared to DMSO-treated cells.](https://figures.cochat.ai/paper-figures/da233f4835d94f63b5b935efbb2537f7/gw501516-activated-ppar-promotes-liver-fibrosis-via-p38-jnk-mapk-induced-hepatic-figure-6.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the PPAR-δ ligand GW501516 was linked to enhanced fibrotic and inflammatory responses due to an increased phosphorylation of p38 and c-Jun-N-terminal kinases.[149].”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295 · cited 1×
“Those studies showed that multiple stress stimuli increased the activity of SAPK/JNK and p38 MAPKs, which in turn activated several transcription factors implicated in cell proliferation and differentiation [26].”
BackgroundPeroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086 · cited 2×
“Distinct genes produce three PPAR isotypes, PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3) [5].”
BackgroundSelf-citationMolecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury
Friedman, S. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2247 · Cited by 2,080 · cited 3×
“This study focused on the role of GW501516-activated PPARβ/δ in mouse liver fibrosis after long-term CCl4 treatment, which is more relevant to liver diseases in human [2,3].”
BackgroundHepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model
Weber, L. W. D., Boll, M., & Stampfl, A. (2003) · Critical Reviews in Toxicology · doi:10.1080/713611034 · Cited by 1,777
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism
Desvergne, B. (1999) · Endocrine Reviews · doi:10.1210/er.20.5.649 · Cited by 1,251
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis
Xu, L., Hui, A. Y., Albanis, E., Arthur, M. J., O’Byrne, S. M., Blaner, W. S., Mukherjee, P., Friedman, S. L., & Eng, F. J. (2005) · Gut · doi:10.1136/gut.2004.042127 · Cited by 1,014 · cited 2×
“These cells express key genes involved in hepatic fibrosis [17].”
BackgroundWiznerowicz, M., & Trono, D. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8957-8951.2003 · Cited by 701 · cited 1×
“In addition, an internal cassette allowed expression of the green fluorescent protein (GFP) marker gene under the control of the elongation factor (EF-1) α promoter [43].”
BackgroundMixed-lineage kinase control of JNK and p38 MAPK pathways
Gallo, K. A., & Johnson, G. L. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm906 · Cited by 572 · cited 2×
“It was previously established that MLK3 phosphorylates and activates the MAP2K isoforms MKK4/7 and MKK3/6, which then activate JNK and p38, respectively [19,20,34,35].”
BackgroundGalli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440 · cited 1×
“PPARγ, activated by glitazones, down-regulates inflammation, collagen synthesis, HSC activation and proliferation [7,8].”
BackgroundThe role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis
Elsharkawy, A. M., Oakley, F., & Mann, D. A. (2005) · Apoptosis · doi:10.1007/s10495-005-1055-4 · Cited by 419 · cited 3×
“Currently, the only effective treatment for end-stage cirrhosis is liver transplantation [1].”
Background
Cited by
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Metabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
Nuclear receptors and nonalcoholic fatty liver disease
Cave, M. C., Clair, H. B., Hardesty, J. E., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.03.002 · Cited by 279
Targeting nuclear receptors for the treatment of fatty liver disease
Tanaka, N., Aoyama, T., Kimura, S., & Gonzalez, F. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.011 · Cited by 212
“, 2012), but GW501516 promoted it (Kostadinova et al., 2012).”
BackgroundJain, M. R., Giri, S. R., Bhoi, B., Trivedi, C., Rath, A., Rathod, R., Ranvir, R., Kadam, S., Patel, H., Swain, P., et al. (2018) · Liver International · doi:10.1111/liv.13634 · Cited by 206
Self-citationFougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 156
Self-citationMetabolic and inflammatory adaptation of reactive astrocytes: role of PPARs
Iglesias, J., Morales, L., & Barreto, G. E. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9833-2 · Cited by 137
Treating NASH by targeting peroxisome proliferator-activated receptors
Staels, B., Butruille, L., & Francque, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.004 · Cited by 108
Cariello, M., Piccinin, E., & Moschetta, A. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.012 · Cited by 120
PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders
Palomer, X., Barroso, E., Pizarro‐Delgado, J., Peña, L., Botteri, G., Zarei, M., Aguilar-Recarte, D., Montori-Grau, M., & Vázquez‐Carrera, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030913 · Cited by 118
Hong, M., Li, S., Wang, N., Tan, H., Cheung, F., & Feng, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030620 · Cited by 110
Zhao, J., Tang, N., Wu, K., Dai, W., Ye, C., Shi, J., Zhang, J., Ning, B., Zeng, X., & Lin, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108005 · Cited by 105
“ERK1 signaling and EMT are known to have significant impact on fibrogenesis[14,16,40].”
BackgroundNuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
Nanotechnology applications for the therapy of liver fibrosis
Giannitrapani, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7242 · Cited by 93
Magadum, A., Ding, Y., He, L., Kim, T., Vasudevarao, M. D., Long, Q., Yang, K., Wickramasinghe, N., Renikunta, H. V., Dubois, N., et al. (2017) · Cell Research · doi:10.1038/cr.2017.84 · Cited by 87
Silva, A. K. S., & Peixoto, C. A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2838-4 · Cited by 96
“In relation to the synthetic agonists, the compound GW501516 [66], which is the most potent and specific, has become the reference PPARβ/δ agonist [67] Despite promising early results, however, the further investigation and development of GW501516 was discontinued after observations in animal studies of its associatio…”
BackgroundPPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases
Monroy-Ramírez, H. C., Galicia‐Moreno, M., Sandoval-Rodriguez, A. S., Meza-Ríos, A., Santos, A., & Armendáriz‐Borunda, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158298 · Cited by 90
“p38–JNK–MAPK in CCl4-induced liver fibrosis [74] and augments fibrotic markers expression such as collagen I, α-SMA, TIMPs, and MMPs [75].”
BackgroundEndocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis
Bazwinsky‐Wutschke, I., Zipprich, A., & Dehghani, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102516 · Cited by 94
“On the one hand these cells include resident macrophage in the liver, i.e., Kupffer cells and HSCs, and on the other hand infiltrating neutrophils, macrophages, T lymphocytes, and dendritic cells.”
BackgroundInfluentialFibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
Manka, P., Zeller, A., & Syn, W.-K. (2019) · Drugs · doi:10.1007/s40265-019-01126-9 · Cited by 76
Ducheix, S., Montagner, A., Théodorou, V., Ferrier, L., & Guillou, H. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.016 · Cited by 86
Self-citationMcVicker, B. L., & Bennett, R. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00318 · Cited by 85
“Consistent with this observation, another study showed that GW501516, administered to mice concomitantly with CCl4, enhanced the degree of fibrosis and inflammation, by a mechanism that involved enhanced proliferation of the hepatic stellate cells (Kostadinova et al., 2012).”
ResultTranscriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ
Tan, N. S., Vázquez‐Carrera, M., Montagner, A., Sng, M. K., Guillou, H., & Wahli, W. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.09.001 · Cited by 84
Self-citationTan, C. K., Zhuang, Y., & Wahli, W. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1280467 · Cited by 70
Self-citationNicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) and liver fibrosis: A review
Mortezaee, K. (2018) · Cell Biochemistry and Function · doi:10.1002/cbf.3351 · Cited by 72
Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis
Han, X., Wu, Y., Yang, Q., & Cao, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107791 · Cited by 75
Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD
Allison, M., Griffin, J., Vacca, M., & Vidal-Puig, A. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562945 · Cited by 63
Insights into the Role of PPARβ/δ in NAFLD
Chen, J., Montagner, A., Tan, N. S., & Wahli, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071893 · Cited by 55
Self-citationZarei, M., Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154342 · Cited by 53
Nuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice
Barbosa‐da‐Silva, S., Souza‐Mello, V., Magliano, D. C., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.02.003 · Cited by 46
Wang, J., Xu, F., Zhu, D., Duan, Y., Chen, J., Sun, X., He, X., Pan, L., Sun, W., & Feng, J. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0003106 · Cited by 41
Cell metabolism-based therapy for liver fibrosis, repair, and hepatocellular carcinoma
Gilgenkrantz, H., Paradis, V., & Lotersztajn, S. (2023) · Hepatology · doi:10.1097/hep.0000000000000479 · Cited by 37
PPARβ Regulates Liver Regeneration by Modulating Akt and E2f Signaling
Liu, H., Fang, Y., Hu, Y. C., Gonzalez, F. J., Fang, J., & Wan, Y. Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065644 · Cited by 40
Zhang, M., Barroso, E., Peña, L., Rada, P., Valverde, Á. M., Wahli, W., Palomer, X., & Vázquez‐Carrera, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117303 · Cited by 34
Self-citationDong, C., Zhou, H., Shen, C., Yu, L., Ding, Y., Zhang, Y., & Guo, Z. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i4.654 · Cited by 37
Nuclear receptors and AMPK: can exercise mimetics cure diabetes?
Wall, C. E., Yu, R. T., Atkins, A. R., Downes, M., & Evans, R. M. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0073 · Cited by 32
“In addition, GW501516 can potentiate liver fibrosis in response to CCl4-induced injury through a pro-proliferative mechanism (Kostadinova et al. 2012).”
BackgroundmiR-706 inhibits the oxidative stress-induced activation of PKCα/TAOK1 in liver fibrogenesis
Yin, R., Guo, D., Zhang, S., & Zhang, X. (2016) · Scientific Reports · doi:10.1038/srep37509 · Cited by 33
The role of JNK signaling pathway in organ fibrosis
Hao, M., Lu, Y., Yao, Z., Wang, P., Chen, Z., Zhou, L., Yang, Q., Sang, X., Wang, K., & Cao, G. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.09.029 · Cited by 36
Hytönen, J. P., Leppänen, O., Bräsen, J. H., Schunck, W., Mueller, D., Jung, F., Mrowietz, C., Jastroch, M., von Bergwelt‐Baildon, M., Kappert, K., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306962 · Cited by 30
“However, data on the role of PPARδ in modulating cell proliferation are controversial, as both increased and decreased cell proliferation rates by synthetic PPARδ ligands have been reported previously.(19,38) Whereas Lim et al(19) reported that adenovirus-mediated overexpression of PPARδ suppresses PDGF-induced VSMC p…”
BackgroundEstep, M., Goodman, Z. D., Sharma, H., Younossi, E., Elarainy, H. A., Baranova, A. V., & Younossi, Z. M. (2014) · Liver International · doi:10.1111/liv.12555 · Cited by 28
Su, G., Li, Z., Wang, R., Lu, Y.-Z., Nan, J., Wu, Y., & Zhao, Y. (2019) · Food & Function · doi:10.1039/c8fo02405g · Cited by 27
Signaling pathways involved in isoprostane-mediated fibrogenic effects in rat hepatic stellate cells
Acquaviva, A., Vecchio, D., Arezzini, B., Comporti, M., & Gardi, C. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.023 · Cited by 26
“Moreover, 15-F2t-IsoP-stimulated cell proliferation and collagen synthesis were completely prevented by preincubation with inhibitors of these MAPKs, selected on the basis of their well-known efficacy on HSCs [43,53,54].”
BackgroundHam, S. A., Hwang, J. S., Yoo, T., Lee, W. J., Paek, K. S., Oh, J., Park, C., Kim, J., Tae, J., Kim, J.-H., et al. (2015) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2015.10.005 · Cited by 23
Global DNA methylation and PTEN hypermethylation alterations in lung tissues from human silicosis
Zhang, X., Jia, X., Mei, L., Min, Z., Chen, Y., & Ye, M. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.07.21 · Cited by 22
“Mitogen-activated protein kinases (MAPK) possesses complicated functions, for example extracellular regulated protein kinases (ERK) promotes cell proliferation, p38 MAPK and c-Jun N-terminal kinase (JNK) mediates cell death or cell survival depending on the stimuli (6-8).”
BackgroundSu, X., Zhou, G., Wang, Y., Xu, Y., Li, L., Yu, R., & Li, D. (2013) · Inflammation · doi:10.1007/s10753-013-9791-z · Cited by 20
Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ
Zhang, M., Barroso, E., Ruart, M., Peña, L., Peyman, M., Aguilar-Recarte, D., Montori-Grau, M., Rada, P., Cugat, C., Montironi, C., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115623 · Cited by 18
Self-citationConditional deletion of CEACAM1 in hepatic stellate cells causes their activation
Muturi, H. T., Ghadieh, H. E., Asalla, S., Lester, S. G., Belew, G. D., Zaidi, S., Abdolahipour, R., Shrestha, A. P., Portuphy, A. O., Stankus, H. L., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102010 · Cited by 19
Busato, S., Ford, H. R., Abdelatty, A. M., Estill, C. T., & Bionaz, M. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.931264 · Cited by 17
“Finally, in mice chronically exposed to carbon tetrachloride (causing fibrosis in the liver), treatment with GW501516 caused a net increase in liver TAG, which was not observed in the PPARδ-knockout population, indicating that activation of PPARδ is required for TAG accumulation under those conditions (49).”
BackgroundLi, X., LI, J., Lu, X., Ma, H., Shi, H., Li, H., Xie, D., Dong, L., & Liang, C. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2270 · Cited by 18
Pilose antler polypeptide protects against sevoflurane‑mediated neurocyte injury
Li, S., & He, J. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9582 · Cited by 15
Zhu, D., Wang, J., Sun, X., Chen, J., Duan, Y., Pan, J., Xu, T., Qin, Y., He, X., & Huang, C. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155414567230 · Cited by 15
“Several studies have shown involvement of the Akt/Bcl-2 pathway in apoptosis in PC12 cells and endothelial cells (Kostadinova et al. 2012; Kumar et al. 2004; Pugazhenthi et al. 2000).”
BackgroundMethodInfluentialPeroxisome proliferator–activated receptor delta and liver diseases
Yamazaki, T., Cable, E. E., & Schnabl, B. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000646 · Cited by 16
Paw, M., Wnuk, D., Madeja, Z., & Michalik, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097721 · Cited by 14
Tang, L., Lü, Q., Cao, H., Qiu, Y., & Tong, N. (2016) · Gene · doi:10.1016/j.gene.2016.02.035 · Cited by 13
“PPARδ activation in the liver also appears to decrease hepatic glucose output, thereby contributing to improved glucose tolerance and insulin sensitivity (Barak et al., 2002; Kostadinova et al., 2012).”
BackgroundQuintero, P., & Arrese, M. A. (2013) · Hepatology · doi:10.1002/hep.26582 · Cited by 13
Zhu, Z., Guan, Y., Gao, S., Guo, F., Liu, D., & Zhang, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117170 · Cited by 12
Roles of nuclear receptors in hepatic stellate cells
Pu, S., Zhou, H., Liu, Y., Liu, J., Guo, Y., & Zhou, H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1949288 · Cited by 13
Luo, L., Xi, C., Xu, T., Zhang, G., Qun, E., & Zhang, W. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.047 · Cited by 10
“The JNK activation could positively adjust HSCs proliferation (Kostadinova et al., 2012), and the proliferation was blocked by the JNK inhibitor.”
BackgroundKim, J. Y., Kim, K. M., Yang, J. H., Cho, S. S., Kim, S. J., Park, S. J., Ahn, S., Lee, G. H., Yang, J. W., Lim, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-57322-w · Cited by 10
Zhang, L., Wu, F., Chang, F., Huang, S., Ma, Y., Chen, S., Zhang, J., & Jiang, H. (2022) · Journal of Proteomics · doi:10.1016/j.jprot.2022.104768 · Cited by 9
Lim, H., & Kwak, H. J. (2024) · Molecules · doi:10.3390/molecules29215189 · Cited by 8
Erol, S. A., Anuk, A. T., Tanaçan, A., Sağır, H. S., Keskin, H. L., Neşelioğlu, S., Erel, Ö., Tekın, Ö. M., & Şahın, D. (2022) · Journal of Turkish Society of Obstetric and Gynecology · doi:10.4274/tjod.galenos.2022.72929 · Cited by 10
PPARβ/δ as a promising molecular drug target for liver diseases: A focused review
Meng, X., Wang, L., Du, Y.-C., Cheng, D., & Zeng, T. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102343 · Cited by 8
Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1
Aldroubi, B., Najjar, J. A., Youssef, T., Rizk, C., Abuamreh, B. A. M., Aramouni, K., Ghadieh, H. E., & Najjar, S. M. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.48 · Cited by 8
MLK 3 as a regulator of disease progression in Non‐alcoholic steatohepatitis
Jiang, J. X., & Torok, N. J. (2014) · Liver International · doi:10.1111/liv.12556 · Cited by 6
Palomer, X., Wang, J.-R., Tang, X., Wu, S., Rodríguez‐Calvo, R., Wahli, W., & Vázquez‐Carrera, M. (2026) · Cells · doi:10.3390/cells15050464 · Cited by 5
Self-citationPPARβ/δ agonist GW0742 mitigates acute liver damage induced by acetaminophen overdose in mice
Wang, L., Chen, J.-H., Zhang, Y.-J., Zhang, M.-B., & Zeng, T. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.117180 · Cited by 5
Wang, F., Wu, Y., Xie, X., Sun, J., & Chen, W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.012 · Cited by 4
Nuclear Receptors in Energy Metabolism
Walth-Hummel, A. A., Herzig, S., & Rohm, M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_4 · Cited by 5
Jiang, X., Yang, X., Han, Y., & Lu, S. (2013) · Tumor Biology · doi:10.1007/s13277-013-0943-4 · Cited by 4
“Ligandactivated PPAR forms a heterodimer with the retinoid X receptor and binds the PPAR response element to regulate transcription of numerous target genes [3, 4], which are involved in cell differentiation, proliferation, immune/inflammation response, and lipid metabolism [5–9].”
Tao, L., Dryden, P., Lowe, A., Wang, G., Dozmorov, I. M., Chang, T., & Reese, T. A. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02337-22 · Cited by 3
Yamazaki, T., Yang, Y., Schöler, D., Yukawa‐Muto, Y., Kouno, T., Harberts, A., Sakane, S., Freund, L., Hsu, C. L., Whisenant, T. C., et al. (2025) · PPAR Research · doi:10.1155/ppar/2935230 · Cited by 2
Li, C. ‐., Zhao, F., Song, J., Zhang, T., Yang, R. L., Xiao, Y., Zheng, Y., Sun, J., & Chen, Z. (2025) · Cell Transplantation · doi:10.1177/09636897251387398 · Cited by 1
Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root
Aggarwal, P., Singh, T., & Alkhouri, N. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00533-x · Cited by 1
The 2012 Ming K Jeang award for excellence in cell & bioscience
Shi, Y. (2013) · Cell & Bioscience · doi:10.1186/2045-3701-3-23
“Chris Lau, considered all research articles published in the journal in 2012 to select the three articles to receive the award [1-3]:”
BackgroundGuo, D., Ji, Q., Lv, T., Kong, B., Ouyang, Q., Dong, Q., & Liu, Y. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5332994
Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease
Li, X., Zhang, J., Wei, B., & Tong, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1775516 · Cited by 4
Rôle du Liver X Receptor dans la régulation transcriptionnelle de la lipogenèse
Ducheix, S. (2013) · theses.fr (ABES) · doi:10.70675/59bbf155z0d40z4bcazad98z24045b25a54f
Cui, Y., Na, M., Zhang, X., Wang, J., Song, L., Wang, Q., Feng, C., Hu, X., Yu, J., Kang, G., et al. (2026) · Environmental Pollution · doi:10.1016/j.envpol.2026.128145
The emerging role of PPARs in primary biliary cholangitis
Palomer, X., Rodríguez‐Calvo, R., Mateo, S. G., Wahli, W., & Vázquez‐Carrera, M. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.05.008
Self-citationHayes, C. M., Cross, D. R., Achour, B., & Ghonem, N. S. (2026) · Cells · doi:10.3390/cells15161442
Metadata
- Authors
- Kostadinova, R., Montagner, A., Gouranton, E., Fleury, S., Guillou, H., Dombrowicz, D., Desreumaux, P., & Wahli, W.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Toxicologie Alimentaire (FR)
- University of Lausanne (CH)
- Inserm (FR)
- Corresponding author
- Wahli, Walter
- ORCID
- Venue
- Cell & Bioscience
- Published
- 2012-10
- Volume
- 2
- Issue
- 1
- Pages
- 34-34
- ISSN
- 2045-3701 (ISSN-L)
- PMC
- PMC3519722
- OpenAlex
- W2120100784
- Cited by
- 83
- References
- 43
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 10 · 2023: 5 · 2022: 6 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 9 · 2015: 6 · 2014: 6 · 2013: 7
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Cell & Bioscience (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- IRIS (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
- SERVAL (Université de Lausanne) (submittedVersion, other-oa)
- Funders
- National Science Foundation
- Institut National de la Santé et de la Recherche Médicale
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Fondation pour la Recherche Médicale
- Université de Lausanne
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- PPARδ, GW501516, liver fibrosis, p38 MAPK, JNK MAPK, phosphatidylinositol 3-kinase/Akt signaling, extracellular matrix deposition, liver inflammation, macrophage recruitment, PPAR target genes, alcoholic liver disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.